139 related articles for article (PubMed ID: 32464229)
1. Effect of uremic state in intestine through a co-culture in vitro intestinal epithelial model.
Garcia A; Macedo MH; Azevedo MJ; Pestana M; Sarmento B; Sampaio-Maia B
Int J Pharm; 2020 Jun; 584():119450. PubMed ID: 32464229
[TBL] [Abstract][Full Text] [Related]
2. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment.
Vaziri ND; Zhao YY; Pahl MV
Nephrol Dial Transplant; 2016 May; 31(5):737-46. PubMed ID: 25883197
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To Predict Intestinal and Colonic Permeability Compared to Caco-2 Monoculture.
Lozoya-Agullo I; Araújo F; González-Álvarez I; Merino-Sanjuán M; González-Álvarez M; Bermejo M; Sarmento B
Mol Pharm; 2017 Apr; 14(4):1264-1270. PubMed ID: 28263609
[TBL] [Abstract][Full Text] [Related]
4. Using 3D gastrointestinal tract in vitro models with microfold cells and mucus secreting ability to assess the hazard of copper oxide nanomaterials.
Ude VC; Brown DM; Stone V; Johnston HJ
J Nanobiotechnology; 2019 May; 17(1):70. PubMed ID: 31113462
[TBL] [Abstract][Full Text] [Related]
5. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity.
Vaziri ND
Curr Opin Nephrol Hypertens; 2012 Nov; 21(6):587-92. PubMed ID: 23010760
[TBL] [Abstract][Full Text] [Related]
6. A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.
Béduneau A; Tempesta C; Fimbel S; Pellequer Y; Jannin V; Demarne F; Lamprecht A
Eur J Pharm Biopharm; 2014 Jul; 87(2):290-8. PubMed ID: 24704198
[TBL] [Abstract][Full Text] [Related]
7. Towards the characterization of an in vitro triple co-culture intestine cell model for permeability studies.
Araújo F; Sarmento B
Int J Pharm; 2013 Dec; 458(1):128-34. PubMed ID: 24120728
[TBL] [Abstract][Full Text] [Related]
8.
Vernay T; Cannie I; Gaboriau F; Gall SD; Tamanai-Shacoori Z; Burel A; Jolivet-Gougeon A; Loréal O; Bousarghin L
Benef Microbes; 2020 Aug; 11(4):391-401. PubMed ID: 32720833
[No Abstract] [Full Text] [Related]
9. Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs.
Antunes F; Andrade F; Araújo F; Ferreira D; Sarmento B
Eur J Pharm Biopharm; 2013 Apr; 83(3):427-35. PubMed ID: 23159710
[TBL] [Abstract][Full Text] [Related]
10. Gut bacterial translocation contributes to microinflammation in experimental uremia.
Wang F; Zhang P; Jiang H; Cheng S
Dig Dis Sci; 2012 Nov; 57(11):2856-62. PubMed ID: 22615020
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease and the gut microbiome.
Hobby GP; Karaduta O; Dusio GF; Singh M; Zybailov BL; Arthur JM
Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1211-F1217. PubMed ID: 30864840
[TBL] [Abstract][Full Text] [Related]
12. Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles.
Schimpel C; Teubl B; Absenger M; Meindl C; Fröhlich E; Leitinger G; Zimmer A; Roblegg E
Mol Pharm; 2014 Mar; 11(3):808-18. PubMed ID: 24502507
[TBL] [Abstract][Full Text] [Related]
13. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P
J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.
Conlin VS; Wu X; Nguyen C; Dai C; Vallance BA; Buchan AM; Boyer L; Jacobson K
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G735-50. PubMed ID: 19661153
[TBL] [Abstract][Full Text] [Related]
15. Effect of secretory immunoglobulin A on bacterial translocation in an enterocyte-lymphocyte co-culture model.
Sawai T; Goldstone N; Drongowski RA; Coran AG; Harmon CM
Pediatr Surg Int; 2001 May; 17(4):275-9. PubMed ID: 11409161
[TBL] [Abstract][Full Text] [Related]
16. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.
Ramezani A; Massy ZA; Meijers B; Evenepoel P; Vanholder R; Raj DS
Am J Kidney Dis; 2016 Mar; 67(3):483-98. PubMed ID: 26590448
[TBL] [Abstract][Full Text] [Related]
17. Translocation of enteropathogenic Escherichia coli across an in vitro M cell model is regulated by its type III secretion system.
Martinez-Argudo I; Sands C; Jepson MA
Cell Microbiol; 2007 Jun; 9(6):1538-46. PubMed ID: 17298392
[TBL] [Abstract][Full Text] [Related]
18. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
Lau WL; Savoj J; Nakata MB; Vaziri ND
Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750
[TBL] [Abstract][Full Text] [Related]
19. [Effect of eicosapentaenoic acid on mRNA expression of tight junction protein ZO-1 in intestinal epithelial cells after Escherichia coli LF82 infection].
Hao LJ; Lin Y; Zhang W; Tian J; Wang Y; Chen PD; Hu CK; Zeng LC; Yang J; Wang BX; Jiang X
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jun; 19(6):693-698. PubMed ID: 28606239
[TBL] [Abstract][Full Text] [Related]
20. Confirmation and prevention of intestinal barrier dysfunction and bacterial translocation caused by methotrexate.
Song D; Shi B; Xue H; Li Y; Yang X; Yu B; Xu Z; Liu F; Li J
Dig Dis Sci; 2006 Sep; 51(9):1549-56. PubMed ID: 16927144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
